Michael has over 25 years of experience in the life sciences industry, and in multiple myeloma specifically, including expertise in preclinical research, clinical development, regulatory strategy and new drug approvals.
He currently serves as chief executive officer (CEO), president and board member of Nereid Therapeutics Inc. He is also a board member for Verastem (VSTM), Kezar Life Sciences (KZR), Incendia Therapeutics, FoRx Therapeutics and BiVictriX Therapeutics.
Previously, Michael served as the co-founder and CEO of Karyopharm, where he guided the company’s transition from a discovery-stage biotechnology company to a commercial-stage organisation and the global approvals of XPOVIO® in multiple myeloma and Non-Hodgkin’s Lymphoma.
Prior to Karyopharm, Michael was CMO of Onyx Pharma, where he led the development of Kyprolis® for multiple myeloma following the Onyx acquisition of Proteolix Inc., where he served as a board member and then CMO. Michael also held the role of President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (which merged into Predix Pharmaceuticals, Inc.).
Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals and held several senior positions at Millennium Predictive Medicine and Biogen. Michael received his MD and PhD from Johns Hopkins Medical School. He trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and Rheumatology at Massachusetts General Hospital. He is board-certified in Internal Medicine and licensed in Massachusetts and Florida.